Investor Relations

Events and Presentations
No upcoming events at this time. Please check again later!
September 29, 2021
View our presentation here
September 13-15, 2021
Tenax Therapeutics will present a company overview and hold virtual investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.
Webcast link to the presentation can be found here and will be available for up to 90 days after the conference.
August 16, 2021
The webinar will feature a presentation by Key Opinion Leader (KOL) Daniel Burkhoff, M.D., Ph.D. (Cardiovascular Research Foundation) who will discuss the current treatment landscape and unmet medical need in treating patients with pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) and how Levosimendan could become an important new treatment option for this patient population. Dr. Burkhoff will be available to answer questions following the formal presentations.
Tenax's Chief Medical Officer, cardiologist Stuart Rich, M.D., will then discuss the clinical development plan for their novel therapy Levosimendan, a first-in-class K-ATP activator/ calcium sensitizer, as the first treatment for PH-HFpEF (WHO Group 2 Pulmonary Hypertension).
A live Q&A session will follow the formal presentations.
January 21, 2021
In addition, the conference call can be accessed by dialing (877) 405-1242 from the U.S. and (201) 389-0852 internationally, followed by the conference ID: 13715313.
An archived webinar recording of the event will be available on the website for approximately 30 days.
November 18, 2020
Tenax Therapeutics will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST.
US/Canada Toll-Free Number: (833) 301-1155
US/Canada International Dial-In Number: (914) 987-7396
Conference ID 5783678

Tenax Therapeutics

Specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension.